|Description||This active molecular is a selective pan-TRK inhibitor. GNE-8525 shows potent antiproliferation activity (IC50 = 0.003 μM) and it shows in vivo antitumor efficacy in tumor xenograft model derived from the KM12 cell line. TRKA are believed to be the key oncogenic driver in many tumors including glioblastoma, melanoma and so on.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
The sulfate salt form of LOXO-101, also called Larotrectinib, is a ATP-competitive inhibitor of tropomyosin receptor kinases and is still under Phase II clinica...
Belizatinib is inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinases (TRK). Belizatinib can bind to and inhibit both ALK and TRK ki...
Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Phase 2.
Tavilermide is a selective, small-molecule partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.
ANA-12 is a selective TrkB antagonist. ANA-12 showed direct and selective binding to TrkB and inhibited processes downstream of TrkB without altering TrkA and T...
GW 441756 is a potent and selective Tropomyosin-related kinase A (TrkA) inhibitor (IC50 = 2 nM), reducing cell proliferation and potentiates the effects of chem...
AZ 23 is a potent and selective tyrosine kinase (Trk) inhibitor with the potential for therapeutic utility in neuroblastoma and multiple other cancer indication...
TPX-0005 is an orally available and potent ATP-competitive inhibitor of ALK/ROS1/TRK (IC50= 5.3 nM for SRC, IC50= 1.01 nM, 1.26 nM and 1.08 nM for mutant ALKs i...
This active molecular is a selective pan-TRK inhibitor. GNE-8525 shows potent antiproliferation activity (IC50 = 0.003 μM) and it shows in vivo antitumor effica...
LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, which activates hippocampal and striatal TrkB and TrkC, and their downstream signaling, and increas...